Exit Menu

The clinical and cost-effectiveness of different treatment pathways for neuropathic pain

Funding body

National Coordinating Centre for Health Technology Assessment


Principal investigator: Prof. Julia Fox-Rushby

Project description

A Markov model with Monte Carlo stimulation is used to provide estimates of the expected costs and quality adjusted life years (QALYs) from alternative pharmacological two causes of neuropathic pain: diabetic neuropathy and post herpetic neuralgia. Cost-effectiveness acceptability curves demonstrates the probability that a particular therapeutic pathway over time is cost-effective for different values decision-makers might have for their willingness to pay per QALY gained. Data for the model is taken from 3 sources: (a) a review of systematic reviews of effectiveness of treatments for NP; (b) a review of resource use, costs and utilities for NP; (c) a questionnaire to an expert panel of physicians.